307 related articles for article (PubMed ID: 9816328)
1. Profound suppression of plasma estrogens by megestrol acetate in postmenopausal breast cancer patients.
Lundgren S; Helle SI; Lonning PE
Clin Cancer Res; 1996 Sep; 2(9):1515-21. PubMed ID: 9816328
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of vorozole (R83842), a new aromatase inhibitor, in postmenopausal women with advanced breast cancer in progression on tamoxifen.
Goss PE; Clark RM; Ambus U; Weizel HA; Wadden NA; Crump M; Walde D; Tye LM; De Coster R; Bruynseels J
Clin Cancer Res; 1995 Mar; 1(3):287-94. PubMed ID: 9815984
[TBL] [Abstract][Full Text] [Related]
3. Endocrine effects of medroxyprogesterone acetate: relation between plasma levels and suppression of adrenal steroids in patients with breast cancer.
van Veelen H; Willemse PH; Sleijfer DT; Sluiter WJ; Doorenbos H
Cancer Treat Rep; 1985 Sep; 69(9):977-83. PubMed ID: 3161613
[TBL] [Abstract][Full Text] [Related]
4. Approval summary: letrozole in the treatment of postmenopausal women with advanced breast cancer.
Cohen MH; Johnson JR; Li N; Chen G; Pazdur R
Clin Cancer Res; 2002 Mar; 8(3):665-9. PubMed ID: 11895893
[TBL] [Abstract][Full Text] [Related]
5. Effects of adjuvant chemohormonal therapy on the ovarian and adrenal function of breast cancer patients.
Rose DP; Davis TE
Cancer Res; 1980 Nov; 40(11):4043-7. PubMed ID: 6451282
[TBL] [Abstract][Full Text] [Related]
6. Endogenous estrogen, androgen, and progesterone concentrations and breast cancer risk among postmenopausal women.
Missmer SA; Eliassen AH; Barbieri RL; Hankinson SE
J Natl Cancer Inst; 2004 Dec; 96(24):1856-65. PubMed ID: 15601642
[TBL] [Abstract][Full Text] [Related]
7. Treatment with high-dose estrogen (diethylstilbestrol) significantly decreases plasma estrogen and androgen levels but does not influence in vivo aromatization in postmenopausal breast cancer patients.
Geisler J; Haynes B; Anker G; Helle H; Ekse D; Dowsett M; Lønning PE
J Steroid Biochem Mol Biol; 2005 Sep; 96(5):415-22. PubMed ID: 16168635
[TBL] [Abstract][Full Text] [Related]
8. Adrenal function under long-term raloxifene administration.
Genazzani AR; Lombardi I; Borgioli G; di Bono I; Casarosa E; Gambacciani M; Palumbo M; Genazzani AD; Luisi M
Gynecol Endocrinol; 2003 Apr; 17(2):159-68. PubMed ID: 12737677
[TBL] [Abstract][Full Text] [Related]
9. [Sequential changes in hormone levels in postmenopausal breast cancer patients under long-term treatment with an aromatase inhibitor. Kanagawa AI Study Group].
Fukuda M; Watanabe H; Suda T; Shimizu S
Gan To Kagaku Ryoho; 1999 Dec; 26(14):2201-8. PubMed ID: 10635305
[TBL] [Abstract][Full Text] [Related]
10. Differential effects of estrogen-androgen and estrogen-only therapy on vasomotor symptoms, gonadotropin secretion, and endogenous androgen bioavailability in postmenopausal women.
Simon J; Klaiber E; Wiita B; Bowen A; Yang HM
Menopause; 1999; 6(2):138-46. PubMed ID: 10374221
[TBL] [Abstract][Full Text] [Related]
11. Steroid hormone profiles in women treated with aminoglutethimide for metastatic carcinoma of the breast.
Samojlik E; Santen RJ; Kirschner MA; Ertel NH
Cancer Res; 1982 Aug; 42(8 Suppl):3349s-3352s. PubMed ID: 7083199
[TBL] [Abstract][Full Text] [Related]
12. Steroid sex hormones and prolactin in postmenopausal women with generalized mammary carcinoma during prolonged dexamethasone treatment.
Borkowski A; L'hermite M; Dor P; Longeval E; Rozencweig M; Muquardt C; Van Cauter E
J Endocrinol; 1977 May; 73(2):235-46. PubMed ID: 140915
[TBL] [Abstract][Full Text] [Related]
13. Influence of progestins on serum hormone levels in postmenopausal women with advanced breast cancer--I. General findings.
Lundgren S; Lønning PE; Utaaker E; Aakvaag A; Kvinnsland S
J Steroid Biochem; 1990 Jun; 36(1-2):99-104. PubMed ID: 2362454
[TBL] [Abstract][Full Text] [Related]
14. Letrozole is superior to anastrozole in suppressing breast cancer tissue and plasma estrogen levels.
Geisler J; Helle H; Ekse D; Duong NK; Evans DB; Nordbø Y; Aas T; Lønning PE
Clin Cancer Res; 2008 Oct; 14(19):6330-5. PubMed ID: 18829517
[TBL] [Abstract][Full Text] [Related]
15. Endocrine and clinical effects of exemestane (PNU 155971), a novel steroidal aromatase inhibitor, in postmenopausal breast cancer patients: a phase I study.
Johannessen DC; Engan T; Di Salle E; Zurlo MG; Paolini J; Ornati G; Piscitelli G; Kvinnsland S; Lonning PE
Clin Cancer Res; 1997 Jul; 3(7):1101-8. PubMed ID: 9815789
[TBL] [Abstract][Full Text] [Related]
16. Clinical and endocrine effects of the oral aromatase inhibitor vorozole in postmenopausal patients with advanced breast cancer.
Johnston SR; Smith IE; Doody D; Jacobs S; Robertshaw H; Dowsett M
Cancer Res; 1994 Nov; 54(22):5875-81. PubMed ID: 7954417
[TBL] [Abstract][Full Text] [Related]
17. Joint effect of insulin-like growth factors and sex steroids on breast cancer risk.
Yu H; Shu XO; Li BD; Dai Q; Gao YT; Jin F; Zheng W
Cancer Epidemiol Biomarkers Prev; 2003 Oct; 12(10):1067-73. PubMed ID: 14578144
[TBL] [Abstract][Full Text] [Related]
18. Increases in serum estrogen levels during major illness are caused by increased peripheral aromatization.
Spratt DI; Morton JR; Kramer RS; Mayo SW; Longcope C; Vary CP
Am J Physiol Endocrinol Metab; 2006 Sep; 291(3):E631-8. PubMed ID: 16670151
[TBL] [Abstract][Full Text] [Related]
19. Dose-related endocrine effects and pharmacokinetics of oral and intramuscular 4-hydroxyandrostenedione in postmenopausal breast cancer patients.
Dowsett M; Cunningham DC; Stein RC; Evans S; Dehennin L; Hedley A; Coombes RC
Cancer Res; 1989 Mar; 49(5):1306-12. PubMed ID: 2917360
[TBL] [Abstract][Full Text] [Related]
20. Preservation of androgen secretion during estrogen suppression with aminoglutethimide in the treatment of metastatic breast carcinoma.
Samojlik E; Veldhuis JD; Wells SA; Santen RJ
J Clin Invest; 1980 Mar; 65(3):602-12. PubMed ID: 6986409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
